{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:46:18Z","timestamp":1792014378720,"version":"4.4.0"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T00:00:00Z","timestamp":1688083200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Antineoplastic drugs produce serious drug-related problems and their management is challenging. DRPs are critical, for saving on therapeutic costs, particularly in resource poor settings within low-middle-income countries such as India. Indicators are clues that helps to detect DRPs within the healthcare organization and minimize overall harm from medications. Indicators enable healthcare professionals to determine the future therapeutic course. And enable healthcare professionals to take a proactive stand, and stay informed and empowered to both prevent and manage DRPs. This study aims to develop evidence-based indicators for detecting potential drug-related problems in ovarian cancer patients.<\/jats:p><jats:p><jats:bold>Patients and Methods:<\/jats:bold> A retrospective study was conducted in the Department of Oncology of a tertiary care teaching hospital in South India. Based on literature search, we developed a list of indicators, which were validated by a Delphi panel of multidisciplinary healthcare professionals (16 members). Based on 2\u00a0years of ovarian cancer data, we performed a feasibility test retrospectively and classified the DRPs according to the Pharmaceutical Care Network Europe classification of DRPs version-9.1.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> The feasibility test identified 130 out of 200 indicators. A total of 803 pDRPs were identified under four main categories: drug selection problem, drug use problem, adverse drug reaction and drug-drug interaction The most frequently observed were ADR 381 (47.45%), DDIs 354 (44.08%), and drug selection problems 62 (7.72%).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Indicators developed by us effectively identified pDRPs in ovarian cancer patients, which can potentially help healthcare professionals in the early detection, timely management, and attenuating severity of DRPs. Identifying the pDDIs can potentially improve interdisciplinary involvement and task sharing, including enhanced pharmacists\u2019 participation within the healthcare team.<\/jats:p>","DOI":"10.3389\/fphar.2023.1203648","type":"journal-article","created":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T18:32:10Z","timestamp":1688149930000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Development of evidence-based indicators for the detection of drug-related problems among ovarian cancer patients"],"prefix":"10.3389","volume":"14","author":[{"given":"Kala Bahadur","family":"Rawal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uday Venkat","family":"Mateti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijith","family":"Shetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chakrakodi Shashidhara","family":"Shastry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazhuvancherry Kesavan","family":"Unnikrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shraddha","family":"Shetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aparna","family":"Rajesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,30]]},"reference":[{"key":"B1","unstructured":"Advantages and disadvantages of protein assisted transport2022"},{"key":"B2","first-page":"p5","volume-title":"Absorption of drugs. Biopharmaceutics and pharmacokinetics- A treatise","author":"Brahmkar","year":"2015"},{"key":"B3","unstructured":"Classification for Drug related problems V9.12022"},{"key":"B4","unstructured":"Consensus document for management of epithelial ovarian cancer2022"},{"key":"B5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40661-017-0054-9","article-title":"Assessment of drug therapy problems among patients with cervical cancer at Kenyatta National Hospital, Kenya","volume":"4","author":"Degu","year":"2017","journal-title":"Gynaecol. Oncol. Res. Pract."},{"key":"B6","first-page":"347","article-title":"Cost of illness: Evidence from a study in five resource-poor locations in India","volume":"127","author":"Dror","year":"2008","journal-title":"Indian J. Med. Res."},{"key":"B7","unstructured":"India's doctor-patient ratio better than WHO norm of 1:1000, government tells Rajya Sabha the Print 2022\n            GhoshA.\n          2022"},{"key":"B8","unstructured":"Globocan 2020: Ovary cancer2022"},{"key":"B9","unstructured":"Globocan 2020: Ovary cancer2023"},{"key":"B10","first-page":"273","article-title":"Efficacy of granulocyte colony stimulating factor as a secondary prophylaxis along with full-dose chemotherapy following a prior cycle of febrile neutropenia","volume":"4","author":"Gupta","year":"2010","journal-title":"Biosci. Trends"},{"key":"B11","first-page":"74","article-title":"Drug utilization study and adverse drug reactions profile of drugs in patients of ovarian cancer in tertiary care teaching hospital","volume":"66","author":"Ingale","year":"2021","journal-title":"Int. J. Pharm. Sci. Rev. Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1186\/s12885-020-06855-9","article-title":"Prevalence and significance of potential drug-drug interactions among cancer patients receiving chemotherapy","volume":"20","author":"Ismail","year":"2020","journal-title":"BMC Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"100743","DOI":"10.1016\/j.cegh.2021.100743","article-title":"Critical analysis of drug related problems among inpatients in the psychiatry department of a tertiary care teaching hospital: A pharmacist led initiative","volume":"11","author":"Jayakumar","year":"2021","journal-title":"Clin. Epidemiol. Glob. Health"},{"key":"B14","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/s41598-020-79380-1","article-title":"Effect of domperidone, ondansetron, olanzapine-containing antiemetic regimen on QTC interval in patients with malignancy: A prospective, observational, single-group, assessor-blinded study","volume":"11","author":"Kamath","year":"2021","journal-title":"Sci. Rep."},{"key":"B15","doi-asserted-by":"publisher","first-page":"206","DOI":"10.4103\/0022-3859.85207","article-title":"A study of drug-drug interactions in cancer patients of a south Indian tertiary care teaching hospital","volume":"57","author":"Kannan","year":"2011","journal-title":"J. Postgrad. Med."},{"key":"B16","unstructured":"Key statistics for ovarian cancer2022"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.18203\/2320-6012.ijrms20204889","article-title":"A study of prescription auditing in inpatient general medicine in tertiary care government hospital","volume":"8","author":"Kumar","year":"2020","journal-title":"Int. J. Res. Med. Sci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e035606","DOI":"10.1136\/bmjopen-2019-035606","article-title":"Scientific, professional and experiential validation of the model of preventive behaviours at work: Protocol of a modified Delphi study","volume":"10","author":"Lecours","year":"2020","journal-title":"BMJ Open"},{"key":"B19","doi-asserted-by":"publisher","first-page":"344","DOI":"10.4082\/kjfm.18.0065","article-title":"The effect of trigger point injections on pain in patients with advanced cancer","volume":"40","author":"Lee","year":"2019","journal-title":"Korean J. Fam. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"120","DOI":"10.3821\/1913-701x(2008)141[120:docift]2.0.co;2","article-title":"Development of clinical indicators for type 2 diabetes","volume":"141","author":"MacKinnon","year":"2008","journal-title":"Can. Pharm. J. (Ott)."},{"key":"B21","first-page":"214","article-title":"Pattern of adverse drug reactions due to cancer chemotherapy in a tertiary care teaching hospital in Nepal","volume":"20","author":"Mallik","year":"2007","journal-title":"Pak J. Pharm. Sci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"287","DOI":"10.2147\/IJWH.S197604","article-title":"Ovarian cancer in the world: Epidemiology and risk factors","volume":"11","author":"Momenimovahed","year":"2019","journal-title":"Int. J. Womens Health"},{"key":"B23","first-page":"263","article-title":"Hypertension in cancer patients","volume":"38","author":"Mouhayar","year":"2011","journal-title":"Tex Heart Inst. J."},{"key":"B24","unstructured":"National institute of cancer surveillance2022"},{"key":"B25","doi-asserted-by":"publisher","first-page":"698907","DOI":"10.3389\/fphar.2021.698907","article-title":"Drug-related problems of patients in primary health care institutions: A systematic review","volume":"2","author":"Ni","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1634\/theoncologist.2018-0807","article-title":"Polypharmacy in patients with ovarian cancer","volume":"24","author":"Oldak","year":"2019","journal-title":"Oncologist"},{"key":"B27","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12960-021-00605-z","article-title":"Conceptual framework for task shifting and task sharing: An international Delphi study","volume":"19","author":"Orkin","year":"2021","journal-title":"Hum. Resour. Health"},{"key":"B28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3329\/dujps.v8i1.5330","article-title":"Pattern of adverse drug reactions due to cancer chemotherapy in tertiary care teaching hospital in Bangladesh","volume":"8","author":"Poddar","year":"2010","journal-title":"Dhaka Univ. J. Pharm. Sci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"77","DOI":"10.4103\/2279-042X.179560","article-title":"Drug interactions in cancer patients: A hidden risk?","volume":"5","author":"Riechelmann","year":"2016","journal-title":"J. Res. Pharm. Pract."},{"key":"B30","unstructured":"Aprepitant. [Updated 2022 sep 22]. In: StatPearls [internet]. Treasure island (FL): StatPearls publishing; 2022 jan\n            RitchieM. K.\n            KohliA.\n          2022"},{"key":"B31","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jobcr.2013.08.001","article-title":"Healthcare inequity and physician scarcity: Empowering non-physician healthcare","volume":"48","author":"Sharma","year":"2013","journal-title":"Econ. Political Wkly."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15226\/2476-2431\/2\/1\/00114","article-title":"Adverse drug reaction due to cancer chemotherapy and its financial burden in different hospitals of Nepal","volume":"2","author":"Shrestha","year":"2017","journal-title":"Int. J. Pharmacovigil."},{"key":"B33","doi-asserted-by":"publisher","first-page":"055","DOI":"10.4172\/1948-5956.1000325","article-title":"Drug related problems in chemotherapy of cancer patients","volume":"7","author":"Sisay","year":"2015","journal-title":"J. Cancer Sci. Ther."},{"key":"B34","unstructured":"Taking multiple medicines safely2023"},{"key":"B35","unstructured":"The Delphi method techniques and applications2022"},{"key":"B36","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2147\/dhps.s11222","article-title":"Development of indicators for identifying adverse drug events in an Indian tertiary care teaching hospital","volume":"2","author":"Thiyagu","year":"2010","journal-title":"Drug Healthc. Patient Saf."},{"key":"B37","unstructured":"Treating ovarian cancer2023"},{"key":"B38","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1093\/annonc\/mdv029","article-title":"Drug-drug interactions in patients treated for cancer: A prospective study on clinical interventions","volume":"26","author":"van Leeuwen","year":"2015","journal-title":"Ann. Oncol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1007\/s11096-009-9312-1","article-title":"Development of an evidence-based checklist for the detection of drug related problems in type 2 diabetes","volume":"31","author":"van Roozendaal","year":"2009","journal-title":"Pharm. World Sci."},{"key":"B40","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1177\/2042098616672572","article-title":"Adverse drug reactions due to cancer chemotherapy in a tertiary care teaching hospital","volume":"8","author":"Wahlang","year":"2017","journal-title":"Ther. Adv. Drug Saf."},{"key":"B41","unstructured":"What is ovarian cancer?2022"},{"key":"B42","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jgo.2015.05.001","article-title":"Drug-related problems in elderly patients with cancer receiving outpatient chemotherapy","volume":"6","author":"Yeoh","year":"2015","journal-title":"J. Geriatr. Oncol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1177\/1715163518802865","article-title":"Oncology pharmacist contributions to treatment with oral anticancer agents in a Japanese community pharmacy setting","volume":"151","author":"Yokoyama","year":"2018","journal-title":"Can. Pharm. J. (Ott)."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1203648\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T18:32:20Z","timestamp":1688149940000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1203648\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,30]]},"references-count":43,"alternative-id":["10.3389\/fphar.2023.1203648"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1203648","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,30]]},"article-number":"1203648"}}